Cabio Biotech (Wuhan) Co (SHSE:688089) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Debt-to-Equity?

Cabio Biotech (Wuhan) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥11.6 Mil. Cabio Biotech (Wuhan) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.7 Mil. Cabio Biotech (Wuhan) Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,500.7 Mil. Cabio Biotech (Wuhan) Co's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cabio Biotech (Wuhan) Co's Debt-to-Equity or its related term are showing as below:

SHSE:688089' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.17
Current: 0.01

During the past 11 years, the highest Debt-to-Equity Ratio of Cabio Biotech (Wuhan) Co was 0.17. The lowest was 0.00. And the median was 0.01.

SHSE:688089's Debt-to-Equity is ranked better than
99.91% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs SHSE:688089: 0.01

Cabio Biotech (Wuhan) Co Debt-to-Equity Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Debt-to-Equity Chart

Cabio Biotech (Wuhan) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

Cabio Biotech (Wuhan) Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.01	0.01	0.01	0.01

Competitive Comparison of Cabio Biotech (Wuhan) Co's Debt-to-Equity

For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cabio Biotech (Wuhan) Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cabio Biotech (Wuhan) Co's Debt-to-Equity falls into.

Cabio Biotech (Wuhan) Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cabio Biotech (Wuhan) Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.102	+	0.662)	/	1476.353
	=	0.01

Cabio Biotech (Wuhan) Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.647	+	0.662)	/	1500.664
	=	0.01

Cabio Biotech (Wuhan) Co (SHSE:688089) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cabio Biotech (Wuhan) Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabio Biotech (Wuhan) Co (SHSE:688089) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073

Website

http://www.cabio.cn

Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.

Executives

Shang Yun	Core technical personnel
Wang Hua Biao	Directors, senior managers
Geng An Feng	senior management
Du Bin	Director
Yi Hua Rong	senior management
Ma Tao	senior management
Li Xiang Yu	senior management
Wu Yu Jun	Supervisors
Xiao Min	senior management
Wang Zhi Ming	senior management
Lu Shu Huan	Core technical personnel
Yi De Wei	Director

Cabio Biotech (Wuhan) Co (SHSE:688089) Headlines

No Headlines